In humans, three main biologics directed toward IL-5 (mepolizumab, reslizumab) IL-5R (benralizumab) have been designed and used as add-on treatments for severe asthma patients with eosinophilic inflammation (Table 1). The gene discussed is IL5; the disease is asthma.